Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theratechnologies Inc (TSX: TH )

2.600 UNCHANGED
Streaming Delayed Price Updated: 12:59 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theratechnologies Inc

< Previous 1 2 3 Next >
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
From Theratechnologies
Via GlobeNewswire
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
From Theratechnologies
Via GlobeNewswire
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancer 
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Operational Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
From Theratechnologies
Via GlobeNewswire
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
From Theratechnologies
Via GlobeNewswire
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide
From Theratechnologies
Via GlobeNewswire
Theratechnologies Completes 1-for-4 Reverse Stock Split
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management
From Theratechnologies
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.